Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service.

Abstract

There is a worldwide pandemic of type 2 diabetes (T2D) and obesity.1 In clinical practice, many patients fail to achieve adequate glycaemic control despite lifestyle advice and maximal doses of oral and injectable medications.2 The evidence suggests that Roux-en-Y gastric bypass (RYGB) is more effective than intensive anti-diabetes medical ther apy, and this has led to a recent joint statement by interna tional diabetes organizations recommending increased use of metabolic surgery in the treatment of T2D with obesity.